<DOC>
	<DOCNO>NCT02565836</DOCNO>
	<brief_summary>This study aim ass fixed-dose regimen activate prothrombin complex concentrate ( FEIBA VH , Baxter ) versus variable , manufacturer recommend , dose regimen inactivate prothrombin complex concentrate ( Kcentra , CSL Behring ) reversal warfarin-associated major hemorrhage .</brief_summary>
	<brief_title>Fixed-dose Activated Versus Variable-dose Inactivated Prothrombin Complex Concentrate Warfarin-associated Major Bleed</brief_title>
	<detailed_description>Warfarin , vitamin K antagonist ( VKA ) , frequently prescribe oral anticoagulant . Warfarin-associated major hemorrhage occur rate 1.7 % 3.4 % routine clinical practice warrant rapid reversal anticoagulation correct supratherapeutic international normalize ratio ( INR ) value . Warfarin inhibit synthesis vitamin K dependent coagulation factor II , VII , IX , X , strategies reversal warfarin-associated coagulopathy aim restoring deficient factor . Four-factor prothrombin complex concentrate ( PCCs ) contain coagulation factor warfarin inhibits attractive option rapid reversal due ease reconstitution requirement blood-type matching . Manufacturer dose recommendation exist PCCs base patient weight , baseline INR , target INR , study suggest fixed dose strategy effort determine efficacious dose VKA-reversal spar adverse event . These study also utilized different PCC formulation , study utilize 4-factor activate PCC ( aPCC ) , denote product containment factor VII activate state . In United States , product availability limited single 4-factor aPCC ( FEIBA VH , Baxter ) indicate hemophilia patient inhibitor single 4-factor inactivate PCC ( Kcentra , CSL Behring ) approve VKA-reversal . Various institution choose utilize off-label fix dose strategy 4-factor aPCC effort administer low possible dose reverse VKAs , others utilize manufacturer recommend dose 4-factor inactivated PCC .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Pretreatment INR lab value great 1.5 Receipt treatment 4factor PCC INR normalization due warfarinassociated major hemorrhage Patients treat PCC urgent invasive procedure without active hemorrhage Patients treat PCC take VKA Unavailable pre posttreatment INR lab value Pregnant patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Vitamin K 1</keyword>
	<keyword>prothrombin complex concentrate</keyword>
	<keyword>warfarin</keyword>
</DOC>